查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930114

精神分裂症藥物市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察，2026-2034 年

Schizophrenia Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 134 Pages | 商品交期: 請詢問到貨日

價格

精神分裂症藥物市場成長因素

全球精神分裂症藥物市場在中樞神經系統 (CNS) 治療領域佔重要佔有率，用於治療嚴重影響認知、情緒和行為功能的嚴重慢性精神疾病。精神分裂症被歸類為精神病性障礙，其特徵是妄想、幻覺、思維混亂和判斷力受損等症狀。雖然精神分裂症無法治愈，但可以透過終身藥物治療（主要使用抗精神病藥物）有效控制病情。

市場規模及預測

根據 Fortune Business Insights 數據顯示，2025 年全球精神分裂症藥物市場規模為 90.8 億美元。預計到 2026 年將達到 94.8 億美元，到 2034 年將成長至 134.1 億美元，在預測期（2026-2034 年）內複合年增長率 (CAGR) 為 4.43%。

市場穩定成長得益於疾病認知度的提高、診斷率的上升、先進抗精神病療法的廣泛應用以及藥物研發的持續創新。

市場概覽

即使症狀緩解，精神分裂症也需要長期使用抗精神病藥物治療以防止復發。這些藥物主要透過調節大腦中的多巴胺活性來發揮作用。在過去幾十年，精神分裂症的治療經歷了從第一代（典型）抗精神病藥物到第二代和第三代（非典型）抗精神病藥物的重大轉變。這種轉變主要得益於療效和副作用的改善。

第一代抗精神病藥物有時伴隨嚴重的錐體外系副作用，例如肌強直、震顫、靜坐不能、肌張力失調和遲發性運動障礙。這些限制加速了安全性更高的新藥的普及應用。

主要市場驅動因子

精神分裂症治療市場的主要驅動因素之一是人們對精神疾病的認識不斷提高，這得益於政府的各項舉措和醫療改革。在美國等國家，聯邦和州立法規定精神科醫療和身體健康醫療的報銷待遇必須相同，從而提高了患者獲得先進精神分裂症治療的機會。

另一個關鍵驅動因素是強大的研發管線，儘管面臨監管和臨床試驗方面的挑戰，目前仍有多種藥物正在研發中。該行業的關注點正日益轉向復發率低、患者依從性高且副作用小的治療方法。

向長效注射劑 (LAI) 的過渡

口服抗精神病藥物的順從性低是精神分裂症治療的一大挑戰，這通常會導致症狀復發和不可逆的認知障礙。這加速了長效注射劑 (LAI) 抗精神病藥物的引入，預計這些藥物將提高依從性並降低復發率。

預計到 2026 年，注射療法將佔市場佔有率的 73.46%，凸顯了其日益增長的臨床重要性。 FDA 批准 Perseris（利培酮緩釋片）等藥物進一步鞏固了這一趨勢。

市場區隔分析

依治療類別

市場細分為第二代、第三代和其他抗精神病藥物。

由於療效顯著且副作用極小，預計第二代抗精神病藥物在預測期內將創造最高的收入。

包括阿立哌唑（Abilify）和阿立哌唑維持治療（Abilify Maintena）在內的第三代藥物也貢獻顯著，而第一代藥物仍然對難治性患者有效。

依治療方法

精神分裂症的治療分為口服和注射療法。

由於依從性提高和復發風險降低，注射藥物市場成長更快。然而，預計到2026年，口服製劑將佔市場佔有率的85.21%，反映出其持續的受歡迎程度。

依通路劃分

預計到 2026 年，醫院藥局將佔市場主導地位，市佔率將達到 38.55%。這主要得益於精神科醫生主導的治療以及長效注射劑 (LAI) 的使用。其次是零售藥局和網路藥局，其中網路藥局預計將實現最高的複合年增長率，這主要得益於數位化通路的日益普及。

區域分析

北美地區在2025年佔了精神分裂症治療市場62.91%的佔有率，預計到2026年，其市場收入將達到59.7億美元。光是美國市場預計到2026年就將達到56.7億美元，主要得益於先進的治療方法和有利的報銷政策。

亞太地區預計將實現最高成長，預計到2026年，日本將達到5.8億美元，中國將達到3.9億美元，印度將達到1.9億美元。歐洲市場也呈現穩定成長，其中德國、英國和法國是主要成長動力。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇

第四章：關鍵考慮因素

  • 長效注射劑（LAI）治療應用日益普及
  • 各地區精神分裂症盛行率
  • 新產品上市
  • 在開發產品分析
  • 各地區監理環境
  • 第一代抗精神病藥物與第二代和第三代抗精神病藥物的比較分析
  • 研發計畫概述精神分裂症治療

第五章：全球精神分裂症治療市場分析、洞察與預測（2021-2034）

  • 主要發現/摘要
  • 市場分析、洞察與預測 - 按治療類別劃分
    • 第三代抗精神病藥物
    • 第二代抗精神病藥物
    • 其他
  • 市場分析、洞察與預測 - 按治療類別劃分
    • 口服
    • 注射
  • 市場分析、洞察與預測 - 按分銷管道劃分
    • 醫院藥房
    • 零售藥房
    • 線上藥房
    • 其他
  • 市場分析、洞察與預測 - 按區域
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美精神分裂症藥物市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲精神分裂症藥物市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞半島
    • 其他地區歐洲

第八章 亞太地區精神分裂症藥物市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲精神分裂症藥物市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章 中東與非洲精神分裂症藥物市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 主要行業趨勢
  • 全球市佔率分析（2025）
  • 競爭格局概覽
  • 主要公司比較分析
  • 公司簡介
    • H.靈北製藥股份有限公司
    • 大塚製藥株式會社
    • 強生製藥股份有限公司
    • 禮來公司
    • 阿斯特捷利康
    • 艾爾建
    • 萬達製藥股份有限公司
    • 住友製藥株式會社
    • Alkermes plc
    • 百時美施貴寶公司
    • 其他主要公司

第十二章：策略建議

Product Code: FBI101531

Growth Factors of schizophrenia drugs Market

The global schizophrenia drugs market represents a critical segment of the central nervous system (CNS) therapeutics landscape, addressing a severe and chronic psychiatric disorder that significantly impacts cognitive, emotional, and behavioral functioning. Schizophrenia is classified as a psychotic disorder and is characterized by symptoms such as delusions, hallucinations, disorganized thinking, and impaired judgment. Although the condition cannot be cured, it can be effectively managed through lifelong pharmacological treatment, primarily using antipsychotic medications.

Market Size and Forecast

According to Fortune Business Insights, the global schizophrenia drugs market was valued at USD 9.08 billion in 2025. The market is projected to reach USD 9.48 billion in 2026 and further expand to USD 13.41 billion by 2034, registering a CAGR of 4.43% during the forecast period (2026-2034).

The steady growth of the market is supported by rising disease awareness, increasing diagnosis rates, growing adoption of advanced antipsychotic therapies, and continuous innovation in drug development.

Market Overview

Schizophrenia requires long-term treatment with antipsychotic drugs, even after symptom remission, to prevent relapse. These medications primarily act by regulating dopamine activity in the brain. Over recent decades, schizophrenia treatment has undergone a major transition from first-generation (typical) antipsychotics to second- and third-generation (atypical) antipsychotics, driven by improved efficacy and reduced side-effect profiles.

First-generation antipsychotics were associated with severe extrapyramidal side effects such as rigidity, tremors, akathisia, dystonia, and tardive dyskinesia. These limitations accelerated the adoption of newer drug classes with better safety outcomes.

Key Market Drivers

One of the primary drivers of the schizophrenia drugs market is increased awareness of mental health disorders, supported by government initiatives and healthcare reforms. In countries such as the United States, federal and state mandates require parity in reimbursement for mental and physical healthcare, improving patient access to advanced schizophrenia treatments.

Another major driver is the strong R&D pipeline, with several drugs under development despite regulatory and clinical trial challenges. The industry focus is increasingly shifting toward treatments with fewer relapses, better patient adherence, and minimal adverse effects.

Shift Toward Long-Acting Injectables (LAIs)

Non-adherence to oral antipsychotic medication is a major challenge in schizophrenia treatment and often leads to symptom relapse and irreversible cognitive damage. This has accelerated the adoption of long-acting injectable (LAI) antipsychotics, which improve adherence and reduce relapse rates.

In 2026, injectable-based treatments are projected to account for a 73.46% market share, highlighting their growing clinical importance. FDA approvals such as Perseris (extended-release risperidone) further reinforce this trend.

Market Segmentation Analysis

By Therapeutic Class

The market is segmented into second-generation, third-generation, and other antipsychotics.

The second-generation antipsychotics segment is expected to generate the highest revenue during the forecast period due to superior efficacy and fewer side effects.

Third-generation drugs, including ABILIFY and ABILIFY MAINTENA, also contribute significantly, while first-generation drugs remain relevant for treatment-resistant patients.

By Treatment Type

Schizophrenia treatment is categorized into oral and injectable therapies.

The injectable segment is witnessing faster growth due to better adherence and reduced relapse risk. However, oral formulations are projected to account for 85.21% market share in 2026, reflecting their continued widespread use.

By Distribution Channel

Hospital pharmacies dominated the market, accounting for 38.55% share in 2026, supported by psychiatrist-led treatment and administration of LAIs. Retail and online pharmacies follow, with online pharmacies expected to register the highest CAGR due to increasing digital access.

Regional Analysis

North America dominated the schizophrenia drugs market with a 62.91% share in 2025, generating USD 5.97 billion in revenue in 2026. The U.S. market alone is projected to reach USD 5.67 billion by 2026, driven by advanced therapeutics and favorable reimbursement policies.

The Asia Pacific region is expected to witness the highest growth, with Japan reaching USD 0.58 billion, China USD 0.39 billion, and India USD 0.19 billion by 2026. Europe is also experiencing steady growth, led by Germany, the U.K., and France.

Competitive Landscape

Key players include H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Janssen Pharmaceuticals, Eli Lilly, AstraZeneca, Alkermes plc, and Bristol-Myers Squibb Company. Market participants are actively investing in LAIs, next-generation antipsychotics, and novel mechanisms such as muscarinic receptor agonists.

Conclusion

In conclusion, the global schizophrenia drugs market is expected to grow steadily from USD 9.08 billion in 2025 to USD 13.41 billion by 2034, driven by increasing mental health awareness, strong R&D pipelines, and rising adoption of second- and third-generation antipsychotics. The growing preference for long-acting injectable therapies and supportive healthcare policies will continue to improve treatment outcomes and sustain long-term market growth across both developed and emerging regions.

Segmentation By Therapeutic Class

  • Second Generation
  • Third Generation
  • Others

By Treatment

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Increasing Adoption of Long Acting Injectable (LAIs) as a Form of Treatment
  • 4.2. Prevalence of Schizophrenia Disorders by Key Regions
  • 4.3. New Product Launches
  • 4.4. Pipeline Analysis
  • 4.5. Regulatory Scenario By Key Regions
  • 4.6. Analysis of First Generation Antipsychotics versus Second & Third Generation Antipsychotics
  • 4.7. Overview of R&D Initiatives in Schizophrenia Treatment

5. Global Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 5.2.1. Third Generation Antipsychotics
    • 5.2.2. Second Generation Antipsychotics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Treatment
    • 5.3.1. Oral
    • 5.3.2. Injectable
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Therapeutic Class
    • 6.2.1. Third Generation Antipsychotics
    • 6.2.2. Second Generation Antipsychotics
    • 6.2.3. Others
  • 6.3. Market Analysis - By Treatment
    • 6.3.1. Oral
    • 6.3.2. Injectable
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Pharmacies
    • 6.4.4. Others
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Therapeutic Class
    • 7.2.1. Third Generation Antipsychotics
    • 7.2.2. Second Generation Antipsychotics
    • 7.2.3. Others
  • 7.3. Market Analysis - By Treatment
    • 7.3.1. Oral
    • 7.3.2. Injectable
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies
    • 7.4.4. Others
  • 7.5. Market Analysis - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Therapeutic Class
    • 8.2.1. Third Generation Antipsychotics
    • 8.2.2. Second Generation Antipsychotics
    • 8.2.3. Others
  • 8.3. Market Analysis - By Treatment
    • 8.3.1. Oral
    • 8.3.2. Injectable
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Pharmacies
    • 8.4.4. Others
  • 8.5. Market Analysis - By Country/ Sub-Region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Therapeutic Class
    • 9.2.1. Third Generation Antipsychotics
    • 9.2.2. Second Generation Antipsychotics
    • 9.2.3. Others
  • 9.3. Market Analysis - By Treatment
    • 9.3.1. Oral
    • 9.3.2. Injectable
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
    • 9.4.4. Others
  • 9.5. Market Analysis - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Therapeutic Class
    • 10.2.1. Third Generation Antipsychotics
    • 10.2.2. Second Generation Antipsychotics
    • 10.2.3. Others
  • 10.3. Market Analysis - By Treatment
    • 10.3.1. Oral
    • 10.3.2. Injectable
  • 10.4. Market Analysis - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
    • 10.4.4. Others
  • 10.5. Market Analysis - By Country/ Sub-Region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles
    • 11.5.1. H. Lundbeck A/S
      • 11.5.1.1. Overview
      • 11.5.1.2. Products & services
      • 11.5.1.3. SWOT Analysis
      • 11.5.1.4. Recent Developments
      • 11.5.1.5. Strategies
      • 11.5.1.6. Financials (Based on Availability)
    • 11.5.2. Otsuka Pharmaceutical Co., Ltd.
      • 11.5.2.1. Overview
      • 11.5.2.2. Products & services
      • 11.5.2.3. SWOT Analysis
      • 11.5.2.4. Recent Developments
      • 11.5.2.5. Strategies
      • 11.5.2.6. Financials (Based on Availability)
    • 11.5.3. Janssen Pharmaceuticals, Inc.
      • 11.5.3.1. Overview
      • 11.5.3.2. Products & services
      • 11.5.3.3. SWOT Analysis
      • 11.5.3.4. Recent Developments
      • 11.5.3.5. Strategies
      • 11.5.3.6. Financials (Based on Availability)
    • 11.5.4. Eli Lilly and Company
      • 11.5.4.1. Overview
      • 11.5.4.2. Products & services
      • 11.5.4.3. SWOT Analysis
      • 11.5.4.4. Recent Developments
      • 11.5.4.5. Strategies
      • 11.5.4.6. Financials (Based on Availability)
    • 11.5.5. AstraZeneca
      • 11.5.5.1. Overview
      • 11.5.5.2. Products & services
      • 11.5.5.3. SWOT Analysis
      • 11.5.5.4. Recent Developments
      • 11.5.5.5. Strategies
      • 11.5.5.6. Financials (Based on Availability)
    • 11.5.6. ALLERGAN
      • 11.5.6.1. Overview
      • 11.5.6.2. Products & services
      • 11.5.6.3. SWOT Analysis
      • 11.5.6.4. Recent Developments
      • 11.5.6.5. Strategies
      • 11.5.6.6. Financials (Based on Availability)
    • 11.5.7. Vanda Pharmaceuticals Inc.
      • 11.5.7.1. Overview
      • 11.5.7.2. Products & services
      • 11.5.7.3. SWOT Analysis
      • 11.5.7.4. Recent Developments
      • 11.5.7.5. Strategies
      • 11.5.7.6. Financials (Based on Availability)
    • 11.5.8. Sumitomo Dainippon Pharma Co., Ltd.
      • 11.5.8.1. Overview
      • 11.5.8.2. Products & services
      • 11.5.8.3. SWOT Analysis
      • 11.5.8.4. Recent Developments
      • 11.5.8.5. Strategies
      • 11.5.8.6. Financials (Based on Availability)
    • 11.5.9. Alkermes plc
      • 11.5.9.1. Overview
      • 11.5.9.2. Products & services
      • 11.5.9.3. SWOT Analysis
      • 11.5.9.4. Recent Developments
      • 11.5.9.5. Strategies
      • 11.5.9.6. Financials (Based on Availability)
    • 11.5.10. Bristol-Myers Squibb Company
      • 11.5.10.1. Overview
      • 11.5.10.2. Products & services
      • 11.5.10.3. SWOT Analysis
      • 11.5.10.4. Recent Developments
      • 11.5.10.5. Strategies
      • 11.5.10.6. Financials (Based on Availability)
    • 11.5.11. Other Prominent Players
      • 11.5.11.1. Overview
      • 11.5.11.2. Products & services
      • 11.5.11.3. SWOT Analysis
      • 11.5.11.4. Recent Developments
      • 11.5.11.5. Strategies
      • 11.5.11.6. Financials (Based on Availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Therapeutic Class, 2021-2034
  • Table 2: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 3: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Therapeutic Class, 2021-2034
  • Table 6: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 7: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Therapeutic Class, 2021-2034
  • Table 10: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 11: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Therapeutic Class, 2021-2034
  • Table 14: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 15: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Therapeutic Class, 2021-2034
  • Table 18: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 19: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Therapeutic Class, 2021-2034
  • Table 22: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 23: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Schizophrenia Drugs Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Schizophrenia Drugs Market Value Share (%), by Therapeutic Class, 2025 & 2034
  • Figure 3: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Second Generation, 2021-2034
  • Figure 4: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Third Generation, 2021-2034
  • Figure 5: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 6: Global Schizophrenia Drugs Market Value Share (%), by Treatment, 2025 & 2034
  • Figure 7: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Oral, 2021-2034
  • Figure 8: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Injectable, 2021-2034
  • Figure 9: Global Schizophrenia Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 10: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Hospital Pharmacies, 2021-2034
  • Figure 11: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Retail Pharmacies, 2021-2034
  • Figure 12: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Online Pharmacies, 2021-2034
  • Figure 13: Global Schizophrenia Drugs Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 14: Global Schizophrenia Drugs Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 15: North America Schizophrenia Drugs Market Value (US$ Mn), by Therapeutic Class, 2025 & 2034
  • Figure 16: North America Schizophrenia Drugs Market Value Share (%), by Therapeutic Class, 2025
  • Figure 17: North America Schizophrenia Drugs Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 18: North America Schizophrenia Drugs Market Value Share (%), by Treatment, 2025
  • Figure 19: North America Schizophrenia Drugs Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 20: North America Schizophrenia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: North America Schizophrenia Drugs Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 22: North America Schizophrenia Drugs Market Value Share (%), By Country, 2025
  • Figure 23: Europe Schizophrenia Drugs Market Value (US$ Mn), by Therapeutic Class, 2025 & 2034
  • Figure 24: Europe Schizophrenia Drugs Market Value Share (%), by Therapeutic Class, 2025
  • Figure 25: Europe Schizophrenia Drugs Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 26: Europe Schizophrenia Drugs Market Value Share (%), by Treatment, 2025
  • Figure 27: Europe Schizophrenia Drugs Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 28: Europe Schizophrenia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 29: Europe Schizophrenia Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 30: Europe Schizophrenia Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 31: Asia Pacific Schizophrenia Drugs Market Value (US$ Mn), by Therapeutic Class, 2025 & 2034
  • Figure 32: Asia Pacific Schizophrenia Drugs Market Value Share (%), by Therapeutic Class, 2025
  • Figure 33: Asia Pacific Schizophrenia Drugs Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 34: Asia Pacific Schizophrenia Drugs Market Value Share (%), by Treatment, 2025
  • Figure 35: Asia Pacific Schizophrenia Drugs Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 36: Asia Pacific Schizophrenia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 37: Asia Pacific Schizophrenia Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 38: Asia Pacific Schizophrenia Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 39: Latin America Schizophrenia Drugs Market Value (US$ Mn), by Therapeutic Class, 2025 & 2034
  • Figure 40: Latin America Schizophrenia Drugs Market Value Share (%), by Therapeutic Class, 2025
  • Figure 41: Latin America Schizophrenia Drugs Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 42: Latin America Schizophrenia Drugs Market Value Share (%), by Treatment, 2025
  • Figure 43: Latin America Schizophrenia Drugs Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Schizophrenia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Schizophrenia Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Schizophrenia Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Schizophrenia Drugs Market Value (US$ Mn), by Therapeutic Class, 2025 & 2034
  • Figure 48: Middle East & Africa Schizophrenia Drugs Market Value Share (%), by Therapeutic Class, 2025
  • Figure 49: Middle East & Africa Schizophrenia Drugs Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 50: Middle East & Africa Schizophrenia Drugs Market Value Share (%), by Treatment, 2025
  • Figure 51: Middle East & Africa Schizophrenia Drugs Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 52: Middle East & Africa Schizophrenia Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 53: Middle East & Africa Schizophrenia Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 54: Middle East & Africa Schizophrenia Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 55: Global Schizophrenia Drugs Market Share (%), By Company, 2025